Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study ...

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

Investors in Rhythm Pharmaceuticals Inc (Symbol: RYTM) saw new options begin trading today, for the May 16th expiration. One of the key inputs that goes into the price an option buyer is willing ...

Investors in Rhythm Pharmaceuticals Inc (Symbol: RYTM) saw new options become available this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

Read about Rhythm Pharmaceuticals Inc (RYTM:XNAS) stock and today's latest news and financial updates.